Sigma Pharmaceuticals Forecast, price target & analysts
Sigma Pharmaceuticals Target price 2026 - Analyst rating & recommendation
Sigma Pharmaceuticals Classifications & Recommendation
Sigma Pharmaceuticals Price Target
| Target Price | A$3.26 |
| Price | A$2.57 |
| Potential |
27.00%
register free of charge
|
| Number of Estimates | 16 |
|
16 Analysts have issued a price target Sigma Pharmaceuticals 2027 .
The average Sigma Pharmaceuticals target price is A$3.26.
This is
27.00%
register free of charge
A$3.99
55.25%
register free of charge
A$2.73
6.11%
register free of charge
|
|
| A rating was issued by 19 analysts: 15 Analysts recommend Sigma Pharmaceuticals to buy, 4 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Sigma Pharmaceuticals stock has an average upside potential 2027 of
27.00%
register free of charge
|
Sales and Margin forecast 2027, 2028 to 2033
| Jun '26 |
2027 Estimates |
|
|---|---|---|
| Revenue Billion A$ | 10.83 | 12.35 |
| 80.53% | 13.95% | |
| Net Margin | 6.55% | 7.05% |
| 25.87% | 7.71% |
17 Analysts have issued a sales forecast Sigma Pharmaceuticals 2027 . The average Sigma Pharmaceuticals sales estimate is
This results in the following potential growth metrics:
17 Sigma Pharmaceuticals Analysts have issued a net profit forecast 2027. The average Sigma Pharmaceuticals net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2027, 2028 to 2033
| Jun '26 |
2027 Estimates |
|
|---|---|---|
| Earnings Per Share A$ | 0.06 | 0.08 |
| 20.00% | 33.33% | |
| P/E | 34.09 | |
| EV/Sales | 2.53 |
17 Analysts have issued a Sigma Pharmaceuticals forecast for earnings per share. The average Sigma Pharmaceuticals EPS is
This results in the following potential growth metrics and future valuations:
Sigma Pharmaceuticals...
Current Sigma Pharmaceuticals Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| ORD MINNETT |
Locked
➜
Locked
|
Locked | Sep 23 2026 |
| BELL POTTER SECURITIES |
Locked
➜
Locked
|
Locked | Sep 22 2026 |
| JEFFERIES |
Locked
➜
Locked
|
Locked | Sep 16 2026 |
| MACQUARIE RESEARCH |
Locked
➜
Locked
|
Locked | Aug 28 2026 |
| E&P |
Locked
➜
Locked
|
Locked | Aug 28 2026 |
| BELL POTTER SECURITIES |
Locked
➜
Locked
|
Locked | Jul 30 2026 |
| BELL POTTER SECURITIES |
Locked
➜
Locked
|
Locked | Jul 02 2026 |
| Analyst Rating | Date |
|---|---|
|
Locked
ORD MINNETT:
Locked
➜
Locked
|
Sep 23 2026 |
|
Locked
BELL POTTER SECURITIES:
Locked
➜
Locked
|
Sep 22 2026 |
|
Locked
JEFFERIES:
Locked
➜
Locked
|
Sep 16 2026 |
|
Locked
MACQUARIE RESEARCH:
Locked
➜
Locked
|
Aug 28 2026 |
|
Locked
E&P:
Locked
➜
Locked
|
Aug 28 2026 |
|
Locked
BELL POTTER SECURITIES:
Locked
➜
Locked
|
Jul 30 2026 |
|
Locked
BELL POTTER SECURITIES:
Locked
➜
Locked
|
Jul 02 2026 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
